Literature DB >> 19470674

Proliferative glomerulonephritis with monoclonal IgG deposits.

Samih H Nasr1, Anjali Satoskar, Glen S Markowitz, Anthony M Valeri, Gerald B Appel, Michael B Stokes, Tibor Nadasdy, Vivette D D'Agati.   

Abstract

Dysproteinemias that result in monoclonal glomerular deposits of IgG are relatively uncommon. Here, we report the largest series of proliferative glomerulonephritis with monoclonal IgG deposits, a form of renal involvement by monoclonal gammopathy that mimics immune-complex glomerulonephritis. We retrospectively identified 37 patients, most of whom were white (81%), female (62%), or older than 50 yr (65%). At presentation, 49% had nephrotic syndrome, 68% had renal insufficiency, and 77% had hematuria. In 30% of the patients, we identified a monoclonal serum protein with the same heavy- and light-chain isotypes as the glomerular deposits (mostly IgG1 or IgG2), but only one patient had myeloma. Histologic patterns were predominantly membranoproliferative (57%) or endocapillary proliferative (35%) with membranous features. Electron microscopy revealed granular, nonorganized deposits, and immunofluorescence demonstrated glomerular deposits that stained for a single light-chain isotype and a single heavy-chain subtype, most commonly IgG3kappa (53%). During an average of 30.3 mo of follow-up for 32 patients with available data, 38% had complete or partial recovery, 38% had persistent renal dysfunction, and 22% progressed to ESRD. Correlates of ESRD on univariate analysis were higher creatinine at biopsy, percentage of glomerulosclerosis, and degree of interstitial fibrosis but not immunomodulatory treatment or presence of a monoclonal spike. On multivariate analysis, higher percentage of glomerulosclerosis was the only independent predictor of ESRD. Only one patient lacking a monoclonal spike at presentation subsequently developed a monoclonal spike and no patient with a monoclonal spike at presentation subsequently developed a hematologic malignancy. We conclude that proliferative glomerulonephritis with monoclonal IgG deposits does not seem to be a precursor of myeloma in the vast majority of patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470674      PMCID: PMC2736767          DOI: 10.1681/ASN.2009010110

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  19 in total

1.  Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition.

Authors:  R Vidal; F Goñi; F Stevens; P Aucouturier; A Kumar; B Frangione; J Ghiso; G Gallo
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Fanconi syndrome in adults. A manifestation of a latent form of myeloma.

Authors:  J E Maldonado; J A Velosa; R A Kyle; R D Wagoner; K E Holley; R M Salassa
Journal:  Am J Med       Date:  1975-03       Impact factor: 4.965

3.  IgG3 is the major source of cryoglobulins in mice.

Authors:  M Abdelmoula; F Spertini; T Shibata; Y Gyotoku; S Luzuy; P H Lambert; S Izui
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

4.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

5.  Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis.

Authors:  Samih H Nasr; Glen S Markowitz; M Barry Stokes; Surya V Seshan; Elsa Valderrama; Gerald B Appel; Pierre Aucouturier; Vivette D D'Agati
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

6.  Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

Authors:  Piero Ruggenenti; Carlos Chiurchiu; Varusca Brusegan; Mauro Abbate; Annalisa Perna; Claudia Filippi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

7.  Aggregation of gamma-G3 proteins: relevance to the hyperviscosity syndrome.

Authors:  J D Capra; H G Kunkel
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

8.  Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features.

Authors:  Jordan L Rosenstock; Glen S Markowitz; Anthony M Valeri; Giuseppe Sacchi; Gerald B Appel; Vivette D D'Agati
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

9.  Single light chain subclass (kappa chain) immunoglobulin deposition in glomerulonephritis.

Authors:  C E Alpers; W H Tu; J Hopper; C G Biava
Journal:  Hum Pathol       Date:  1985-03       Impact factor: 3.466

10.  A new mouse immunoglobulin: IgG3.

Authors:  H M Grey; J W Hirst; M Cohn
Journal:  J Exp Med       Date:  1971-02-01       Impact factor: 14.307

View more
  106 in total

1.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

2.  A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome.

Authors:  Martina Soldarini; Lucia Farina; Augusto Genderini; Niccolo Bolli
Journal:  BMJ Case Rep       Date:  2017-07-14

3.  Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft.

Authors:  Samih H Nasr; Sanjeev Sethi; Lynn D Cornell; Mary E Fidler; Mark Boelkins; Fernando C Fervenza; Fernando G Cosio; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

4.  Chronological change of renal pathological findings in the proliferative glomerulonephritis with monoclonal IgG deposits considered to have recurred early after kidney transplantation.

Authors:  Takayuki Katsuno; Masashi Kato; Takashi Fujita; Naotake Tsuboi; Ryohei Hattori; Yasuhiko Ito; Shoichi Maruyama
Journal:  CEN Case Rep       Date:  2019-02-25

5.  Membranoproliferative glomerulonephritis: the times they are a-changin'.

Authors:  Jan Willem Cohen Tervaert
Journal:  Clin Exp Nephrol       Date:  2013-08-28       Impact factor: 2.801

Review 6.  Differential diagnosis of glomerular disease: a systematic and inclusive approach.

Authors:  Lee A Hebert; Samir Parikh; Jason Prosek; Tibor Nadasdy; Brad H Rovin
Journal:  Am J Nephrol       Date:  2013-09-13       Impact factor: 3.754

Review 7.  The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Authors:  Sanjeev Sethi; S Vincent Rajkumar; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2018-04-27       Impact factor: 10.121

Review 8.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

9.  Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance.

Authors:  Mitchell H Rosner; Amaka Edeani; Motoko Yanagita; Ilya G Glezerman; Nelson Leung
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

Review 10.  What is the significance of monoclonal gammopathy of undetermined significance?

Authors:  Catherine Atkin; Alex Richter; Elizabeth Sapey
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.